Drug profile · INN
atezolizumab
TECENTRIQ
- US status
- approved
- Patents linked
- 0
- News articles
- 3
Quick answer
atezolizumab (TECENTRIQ) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
Key facts
Related news
FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC
The FDA has approved Atezolizumab as an adjuvant treatment for patients with ctDNA MRD-positive muscle-invasive bladder cancer (MIBC), marking a significant advancement in oncology. This approval is expected to influence investment strategies and competitive dynamics in the pharmaceutical sector.
FDA Approves Atezolizumab for Muscle-Invasive Bladder Cancer
The FDA has approved Atezolizumab for muscle-invasive bladder cancer, marking a significant advancement in oncology treatment options. This approval has important implications for investors and pharmaceutical teams.
FDA Approves Tecentriq for Extensive-Stage Small Cell Lung Cancer
The FDA has granted approval for Tecentriq, a groundbreaking treatment for extensive-stage small cell lung cancer, enhancing options for patients in need.
Frequently asked questions
What is atezolizumab?
atezolizumab (TECENTRIQ) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for atezolizumab?
TECENTRIQ is a marketed brand name for atezolizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of atezolizumab?
atezolizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.